Literature DB >> 2762767

Complement-fixing properties of human IgA antibodies. Alternative pathway complement activation by plastic-bound, but not specific antigen-bound, IgA.

M W Russell1, B Mansa.   

Abstract

The complement-fixing properties of human IgA antibodies bound to specific antigen, or coated directly on plastic surfaces, were examined in comparison with those of IgG antibodies. Use was made of antigen-binding (anti-staphylococcal alpha-toxin) IgA and IgG monoclonal antibodies and normal polyclonal IgA and IgG, purified greater than 99.9% by avoidance of denaturing processes. Complement-fixation ELISA was used, with a high density of biotin-conjugated staphylococcal alpha-toxin bound to avidin-coated plates for the efficient capture of antibodies, and conditions were adjusted for the assessment of classical and alternative pathways of complement activation. Although IgA coated directly on plastic surfaces activated the alternative complement pathway in a dose-dependent manner, IgA antibodies bound to antigen failed to fix complement by either classical or alternative pathways. In contrast, IgG antibodies, either bound to antigen or coated directly on plastic, activated complement mainly by the classical pathway. It was concluded that the complexation of IgA antibodies with antigen is insufficient to elicit complement activation: rather a degree of denaturation seems to play a part in the expression of alternative complement pathway-activating properties by IgA.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2762767     DOI: 10.1111/j.1365-3083.1989.tb01199.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  28 in total

1.  Ro/SSA and La/SSB specific IgA autoantibodies in serum of patients with Sjögren's syndrome and systemic lupus erythematosus.

Authors:  N Pourmand; M Wahren-Herlenius; I Gunnarsson; E Svenungsson; B Löfström; Y Ioannou; D A Isenberg; C G Magnusson
Journal:  Ann Rheum Dis       Date:  1999-10       Impact factor: 19.103

Review 2.  Progress in molecular and genetic studies of IgA nephropathy.

Authors:  J Novak; B A Julian; M Tomana; J Mesteck
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

Review 3.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 4.  The structure and function of human IgA.

Authors:  M A Kerr
Journal:  Biochem J       Date:  1990-10-15       Impact factor: 3.857

5.  Complement-coated antibody-transfer (CCAT); serum IgA1 antibodies intercept and transport C4 and C3 fragments and preserve IgG1 deployment (PGD).

Authors:  Robert J Boackle; Quang L Nguyen; Renata S Leite; Xiaofeng Yang; Jana Vesely
Journal:  Mol Immunol       Date:  2005-03-05       Impact factor: 4.407

6.  B cell-intrinsic and -extrinsic regulation of antibody responses by PARP14, an intracellular (ADP-ribosyl)transferase.

Authors:  Sung Hoon Cho; Ariel Raybuck; Mei Wei; John Erickson; Ki Taek Nam; Reagan G Cox; Alyssa Trochtenberg; James W Thomas; John Williams; Mark Boothby
Journal:  J Immunol       Date:  2013-08-16       Impact factor: 5.422

7.  Intestinal IgA: novel views on its function in the defence of the largest mucosal surface.

Authors:  J Mestecky; M W Russell; C O Elson
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

Review 8.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

9.  Mesangial cell autoantigens in immunoglobulin A nephropathy and Henoch-Schönlein purpura.

Authors:  D J O'Donoghue; A Darvill; F W Ballardie
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

10.  Inhibition of Streptococcus mutans adherence to saliva-coated hydroxyapatite by human secretory immunoglobulin A (S-IgA) antibodies to cell surface protein antigen I/II: reversal by IgA1 protease cleavage.

Authors:  G Hajishengallis; E Nikolova; M W Russell
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.